Skip to main content

Table 1 Baseline patient characteristics (n = 149). Values are numbers (percentages) unless stated otherwise

From: Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial

Characteristics

Intervention (n = 75)

Control (n = 74)

Mean (SD) age [years]

64.7 (12.4)

69.0 (8.8)

Men

46 (61)

51 (69)

Civil status

 Unmarried

7 (9)

10 (14)

 Married

46 (61)

48 (65)

 Divorced/widowed

22 (29)

16 (22)

Highest level of education at school [n]

 Primary school

10 (13)

11 (15)

 Apprenticeship

38 (50)

52 (70)

 Higher professional education

14 (19)

6 (8)

 University-entrance Diploma/Commercial college

2 (3)

1 (1)

 University / Collage of higher education

11 (15)

4 (6)

Employment status [n]

 Active worker

23 (31)

15 (20)

 Pensioner

47 (63)

57 (77)

 Never active worker

5 (6)

2 (3)

Diagnosed lung disease

 Asthma

30 (40)

16 (22)

 COPD

32 (43)

45 (61)

 Asthma-COPD- overlap

13 (17)

13 (17)

Smoking status

 Current smoker

16 (21.3)

12 (16.2)

 Non-smokers

19 (25.3)

14 (18.9)

 Ex-smokers

40 (53.3)

48 (64.9)

Mean (SD) pack-years [n]

28.6 (32.8)

41.2 (34.3)

History of allergy

35 (47)

29 (39)

Mean (SD) body mass index [kg/m2]

26.5 (4.2)

28.0 (5.6)

GOLD stage

 1 (FEV1 > 80% predicted), mild

2 (4)a

6 (10)b

 2 (FEV1 50–80% predicted), moderate

20 (45)a

24 (42)b

 3 (FEV1 30–50% predicted), severe

19 (42)a

21 (36)b

 4 (FEV1 < 30% predicted), very severe

4 (9)a

7 (12)b

Mean (SD) FEV1 predicted [%]

63.9 (25.0)

56.5 (23.5)c

Mean (SD) FEV1/FVC predicted [%]

70.3 (20.7)

67.1 (22.1)c

Mean SGRQ symptoms score (SD)

45.7 (21.5)

48.7 (25.6)

Mean SGRQ activity score (SD)

45.2 (19.3)

52.4 (23.7)

Mean SGRQ impact score (SD)

21.8 (14.6)

29.3 (20.7)

Mean SGRQ total score (SD)

32.5 (14.7)

39.6 (20.3)

Mean (SD) inhaled medication [n]

1.9 (0.8)

2.0 (0.8)

Mean (SD) co-morbidities [n]

1.8 (1.6)

2.2 (1.7)

Co-existing illnesses [n]

 Diseases of the cardiovascular system

44 (59)

46 (62)

 Endocrine, nutritional and metabolicdiseases

18 (24)

19 (26)

 Diseases of the gastrointestinal system

10 (13)

8 (11)

 Diseases of the musculoskeletal system and connective tissue

16 (21)

16 (22)

Mean (SD) exacerbations (last 12 months) [n]

1.7 (0.9)

2.07 (1.4)

Mean (SD) exacerbations with hospitalisation (last 12 months) [n]

0.4 (0.6)

0.7 (1.0)

Medication [n]

 LABA/LAMA combinations

10 (13)

9 (12)

 LABA/ICS combinations

52 (69)

53 (72)

 LAMA

26 (35)

41 (55)

 LABA

14 (19)

6 (8)

 ICS

10 (13)

5 (7)

 SABA

32 (43)

34 (46)

 SABA/SAMA combinations

2 (2.7)

2 (2.7)

Number of inhaled medication at baseline

 1

22 (29.3)

23 (31.1)

 2

36 (48.0)

27 (36.5)

 3

16 (21.3)

23 (31.1)

 4

1 (1.3)

1 (1.4)

  1. an = 45; bn = 58; cn = 72; FEV1, Forced expiratory volume in 1 sec; FVC Forced vital capacity, LABA Long acting beta2-agonist, LAMA Long acting muscarinic antagonist, ICS Inhaled corticosteroid, SABA Short acting beta2-agonist, SGRQ St. George Respiratory Questionnaire